MedTrace Logo

Development and Implementation of an HIV-testing Intervention for Primary Care in Belgium

NCT04056156 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6211

Last updated 2021-06-03

No results posted yet for this study

Summary

An innovative HIV-testing strategy is developed based on mathematical modeling results on undiagnosed HIV and being implemented in primary care settings in Belgian's Flemish region.

The systematically developed intervention aims at increasing the number of targeted HIV tests in primary care in order to identify people with undiagnosed HIV.

The intervention tool is an HIV-screening advice targeting general practitioners (GPs), combining indicator-condition based screening and target-group based screening. A group-level training to apply this advice in routine practice is being delivered as part of the continuing medical education through GP-associations.

The intervention is implemented across Flanders adopting a modified stepped wedged design: two different intervention levels (delivering written/online information on the HIV testing advice versus information plus group-level training) are being compared with a control condition (no intervention, i.e. standard practice) based on surveillance data. A mixed-method study evaluates the intervention's effectiveness, feasibility, and acceptability.

Conditions

  • HIV Infections

Interventions

BEHAVIORAL

HIV-screening advice

To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail

BEHAVIORAL

HIV-testing advice plus group-level training

To increase specific HIV-testing behavior among GPs a targeted HIV-testing advice is spread to participants through an electronic mail and an additional face-to-face group-level training is provided.

Sponsors & Collaborators

  • Sciensano

    collaborator OTHER_GOV

  • Institute of Tropical Medicine, Belgium

    lead OTHER

Principal Investigators

  • Christiana Noestlinger, PhD · Institute of Tropical Medicine

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04056156 on ClinicalTrials.gov